焦虑生物标志物的发现、优先排序和验证。研究中使用的队列，描述每个步骤的发现流程、优先级排序、生物标记物验证和独立测试队列。B发现队列纵向学科内分析。phchp# ##是每个受试者的研究ID。v#表示访问次数。红色是高焦虑就诊，蓝色是低焦虑就诊。C聚合功能基因组学证据。D在验证步骤中，使用方差分析(ANOVA)评估生物标记物从重度焦虑验证组到高焦虑、低焦虑发现组，再到重度焦虑验证组的逐步变化。N =测试访问次数。直方图描述了验证中顶部增加和顶部减少的生物标志物。 E Scoring at each of the steps. Discovery probesets are identified based on their score for tracking anxiety with a maximum of 6 points (33% (2 pt), 50% (4 pt) and 80% (6 pt)). Prioritization with CFG for prior evidence of involvement in anxiety disorders. In the prioritization step probesets are converted to their associated genes using Affymetrix annotation and GeneCards. Genes are prioritized and scored using CFG for anxiety evidence, with a maximum of 12 points. Genes scoring at least 6 points out of a maximum possible of 18 total internal and external scores points are carried to the validation step. Validation in an independent cohort of psychiatric patients with clinically severe anxiety (STAI State ≥ 55 and SAS-4 > =60). Four biomarkers were nominally significant, and 57 biomarkers were stepwise changed. We selected for further testing in independent cohorts the top candidate biomarkers, with a total score after the first 3 steps (CFE3) of 8 and above (n = 95 biomarkers). Credit:《分子精神病学》(2023)。DOI: 10.1038 / s41380 - 023 - 01998 - 0
